236 related articles for article (PubMed ID: 11941539)
41. RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans.
Shea PR; Ishwad CS; Bunker CH; Patrick AL; Kuller LH; Ferrell RE
Prostate; 2008 Mar; 68(4):354-9. PubMed ID: 18189233
[TBL] [Abstract][Full Text] [Related]
42. CHEK2 variants associate with hereditary prostate cancer.
Seppälä EH; Ikonen T; Mononen N; Autio V; Rökman A; Matikainen MP; Tammela TL; Schleutker J
Br J Cancer; 2003 Nov; 89(10):1966-70. PubMed ID: 14612911
[TBL] [Abstract][Full Text] [Related]
43. Carriage of mutations R462Q (rs 486907) and D541E (rs 627928) of the RNASEL gene and risk factors in patients with prostate cancer in Burkina Faso.
Kadanga E; Zouré AA; Zohoncon TM; Traoré L; Ky BD; Yonli AT; Traoré DDA; Bazié BVJTE; Sombié HK; Sorgho PA; Tovo SFA; Traoré K; Ouedraogo TC; Djigma FW; Simpore J
BMC Med Genomics; 2022 Jun; 15(1):123. PubMed ID: 35655265
[TBL] [Abstract][Full Text] [Related]
44. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region.
Baffoe-Bonnie AB; Smith JR; Stephan DA; Schleutker J; Carpten JD; Kainu T; Gillanders EM; Matikainen M; Teslovich TM; Tammela T; Sood R; Balshem AM; Scarborough SD; Xu J; Isaacs WB; Trent JM; Kallioniemi OP; Bailey-Wilson JE
Hum Genet; 2005 Aug; 117(4):307-16. PubMed ID: 15906096
[TBL] [Abstract][Full Text] [Related]
45. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.
Beuten J; Gelfond JA; Franke JL; Shook S; Johnson-Pais TL; Thompson IM; Leach RJ
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):588-99. PubMed ID: 20086112
[TBL] [Abstract][Full Text] [Related]
46. [G138A polymorphism of the RNASEL gene and its association with the development of prostate cancer. Preliminary study].
Zabala W; Delgado C; Pardo T; Borjas L; Rojas-Atencio A; Reyes F; Quintero JM
Invest Clin; 2009 Sep; 50(3):295-301. PubMed ID: 19961052
[TBL] [Abstract][Full Text] [Related]
47. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.
Orr-Urtreger A; Bar-Shira A; Bercovich D; Matarasso N; Rozovsky U; Rosner S; Soloviov S; Rennert G; Kadouri L; Hubert A; Rennert H; Matzkin H
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):474-9. PubMed ID: 16537704
[TBL] [Abstract][Full Text] [Related]
48. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer.
Rantapero T; Wahlfors T; Kähler A; Hultman C; Lindberg J; Tammela TL; Nykter M; Schleutker J; Wiklund F
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32183364
[TBL] [Abstract][Full Text] [Related]
49. The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1.
Krüger S; Engel C; Bier A; Silber AS; Görgens H; Mangold E; Pagenstecher C; Holinski-Feder E; von Knebel Doeberitz M; Royer-Pokora B; Dechant S; Pox C; Rahner N; Müller A; Schackert HK;
Cancer Lett; 2007 Jul; 252(1):55-64. PubMed ID: 17224235
[TBL] [Abstract][Full Text] [Related]
50. RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells.
Dayal S; Zhou J; Manivannan P; Siddiqui MA; Ahmad OF; Clark M; Awadia S; Garcia-Mata R; Shemshedini L; Malathi K
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257035
[TBL] [Abstract][Full Text] [Related]
51. Positive selection on the gene RNASEL: correlation between patterns of evolution and function.
Jin W; Wu DD; Zhang X; Irwin DM; Zhang YP
Mol Biol Evol; 2012 Oct; 29(10):3161-8. PubMed ID: 22513284
[TBL] [Abstract][Full Text] [Related]
52. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.
Rennert H; Zeigler-Johnson CM; Addya K; Finley MJ; Walker AH; Spangler E; Leonard DG; Wein A; Malkowicz SB; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):949-57. PubMed ID: 15824169
[TBL] [Abstract][Full Text] [Related]
53. ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.
Siltanen S; Syrjäkoski K; Fagerholm R; Ikonen T; Lipman P; Mallott J; Holli K; Tammela TL; Järvinen HJ; Mecklin JP; Aittomäki K; Blomqvist C; Bailey-Wilson JE; Nevanlinna H; Aaltonen LA; Schleutker J; Vahteristo P
Eur J Hum Genet; 2008 Aug; 16(8):983-91. PubMed ID: 18337727
[TBL] [Abstract][Full Text] [Related]
54. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
[TBL] [Abstract][Full Text] [Related]
55. Low frequency of allelic imbalance at the prostate cancer susceptibility loci HPC1 and 1p36 in Swedish men with hereditary prostate cancer.
Ahman AK; Jonsson BA; Damber JE; Bergh A; Emanuelsson M; Grönberg H
Genes Chromosomes Cancer; 2000 Dec; 29(4):292-6. PubMed ID: 11066072
[TBL] [Abstract][Full Text] [Related]
56. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1.
Grönberg H; Xu J; Smith JR; Carpten JD; Isaacs SD; Freije D; Bova GS; Danber JE; Bergh A; Walsh PC; Collins FS; Trent JM; Meyers DA; Isaacs WB
Cancer Res; 1997 Nov; 57(21):4707-9. PubMed ID: 9354426
[TBL] [Abstract][Full Text] [Related]
57. A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
Kote-Jarai Z; Jugurnauth S; Mulholland S; Leongamornlert DA; Guy M; Edwards S; Tymrakiewitcz M; O'Brien L; Hall A; Wilkinson R; Al Olama AA; Morrison J; Muir K; Neal D; Donovan J; Hamdy F; Easton DF; Eeles R; ;
Br J Cancer; 2009 Jan; 100(2):426-30. PubMed ID: 19127258
[TBL] [Abstract][Full Text] [Related]
58. Association of RNASEL and 8q24 variants with the presence and aggressiveness of hereditary and sporadic prostate cancer in a Hispanic population.
San Francisco IF; Rojas PA; Torres-Estay V; Smalley S; Cerda-Infante J; Montecinos VP; Hurtado C; Godoy AS
J Cell Mol Med; 2014 Jan; 18(1):125-33. PubMed ID: 24224612
[TBL] [Abstract][Full Text] [Related]
59. Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.
Alvarez-Cubero MJ; Pascual-Geler M; Martinez-Gonzalez LJ; Expósito Ruiz M; Saiz M; Cozar JM; Lorente JA
Urol Oncol; 2016 Oct; 34(10):431.e1-8. PubMed ID: 27318894
[TBL] [Abstract][Full Text] [Related]
60. Perspective: prostate cancer susceptibility genes.
Simard J; Dumont M; Soucy P; Labrie F
Endocrinology; 2002 Jun; 143(6):2029-40. PubMed ID: 12021166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
